Endometriosis and Painful Sex on a GLP-1

The fast answer

If sex hurts deep inside rather than at the entrance, lubricant is not going to fix it, and the reason is that you are dealing with a different problem than the one everyone assumes.

Painful sex is one of the three cardinal symptoms of endometriosis, a condition that affects up to 10% of women — around 9 million in the US — and 90% of people with endometriosis report pelvic pain, including pain with sex¹.

Two things to take from this page:

• Where it hurts is diagnostic information. Entry pain and deep pain point at different structures and different fixes.
• A normal exam and a normal scan do not rule endometriosis out. That is stated outright in the current JAMA review, and it is the single most useful sentence here if you have already been sent home once¹.

Some links below are to programs we may earn a referral fee from; it never changes our ranking. See our disclosure.

Entry pain and deep pain are not the same problem

This is the distinction worth getting right before any appointment, because it changes what gets investigated.

Pain at the entrance — burning, stinging, a raw or sandpapery feeling in the first inch — is usually about tissue and lubrication. That is the territory of vaginal dryness and the genitourinary changes that come with hormonal shifts, and it is covered in vaginal changes on a GLP-1. Lubricant helps, because lubricant is the right tool for that job.

Pain deep inside — a bruised, aching or stabbing sensation with deep penetration, often worse in certain positions, sometimes lingering for hours or into the next day — is not a lubrication problem. Lube cannot reach it. Deep pain points at structures behind the vaginal wall, and endometriosis is one of the most common explanations.

Pain that feels like a muscle guarding or clamping is a third thing again, and it has its own treatment ladder in pelvic floor PT on a GLP-1.

If you take one sentence to your clinician, make it the location: "It hurts deep, not at the opening, and it is worse in some positions." That sentence does more work than "sex is painful."

What endometriosis actually is, in numbers

Endometriosis is a chronic, estrogen-dependent, inflammatory disease in which endometrial-like tissue grows outside the lining of the uterus¹.

The figures from the 2025 JAMA review are worth having in front of you:

• It affects up to 10% of women worldwide during their reproductive years¹.
• 90% report pelvic pain — painful periods, non-menstrual pelvic pain, and pain with sex¹.
• 26% report infertility¹.
• Diagnosis is delayed by an average of 5 to 12 years after symptoms start, and most women see three or more clinicians before getting it¹.

That last figure is not a footnote. If you have raised this before and been told it is normal, you are inside the statistical norm for how this condition gets handled — not an outlier, and not imagining it.

And the diagnostic caveat matters just as much: a definitive diagnosis requires surgical visualization of the lesions, but a suspected clinical diagnosis can be made from symptoms plus examination and imaging — and a normal physical exam and normal imaging do not exclude endometriosis¹. A clear ultrasound is not an all-clear.

The part that matters if you are losing weight

Here is a fact that sounds alarming until you look at what it means, so let us be precise about it.

The JAMA review lists lower body mass index among the risk factors for endometriosis, alongside younger age at first period, shorter cycles, and never having given birth¹.

This is not evidence that losing weight gives you endometriosis, and it is not evidence that a GLP-1 causes or worsens it. That association comes from observing who turns out to have the disease. Nobody has shown a causal direction, and no study has tested GLP-1 medications against endometriosis outcomes at all.

The honest implication runs the opposite way from the usual assumption. Endometriosis is not a condition of larger bodies that you leave behind as the scale moves. If anything, being smaller makes it less likely to be the first thing a clinician thinks of — which, in a population of women who are actively losing weight, is a good reason to raise it yourself rather than wait for it to be raised.

If your deep pain started long before the medication did, the medication is not the story. Say that out loud too, because "it started on the GLP-1" and "I noticed it on the GLP-1" get treated very differently.

The interaction nobody flags

This is the piece that does not appear on any endometriosis page, and it is worth five minutes of your prescriber's time.

First-line treatment for endometriosis is hormonal suppression — combined estrogen-progestin contraceptives, or progestins — for women who are not trying to conceive immediately¹. A very large number of women manage endometriosis with a daily pill.

Tirzepatide reduces exposure to swallowed hormones. The Zepbound and Mounjaro labels both instruct patients on oral contraceptives to switch to a non-oral method or add a barrier method for four weeks after the first dose and four weeks after each dose increase^2,3.

Now put those together. The labels describe that window in terms of contraceptive efficacy — the risk of an unintended pregnancy. They say nothing about symptom control. Whether those same four-week windows loosen hormonal suppression of endometriosis has not been studied by anyone, and this page is not going to pretend otherwise.

What that leaves you with is a reasonable question rather than a finding: if you manage endometriosis with an oral hormonal medication and you are starting or escalating tirzepatide, it is worth asking your prescriber whether a non-oral route makes more sense for you — and worth noticing whether your pain pattern shifts in the weeks after a dose step-up. The contraceptive side of this is covered in full in GLP-1s and birth control.

On semaglutide (Wegovy, Ozempic), that oral-contraceptive warning does not appear on the label at all⁴, so this question does not arise in the same way.

What to actually do

Lead with location and timing. Deep versus entry, which positions, and whether it lingers afterwards. Add whether it tracks your cycle — endometriosis pain classically does.

Say the word. Ask directly: "Could this be endometriosis?" Given a 5-to-12-year average delay and three-plus clinicians, naming it yourself measurably shortens the path¹.

Do not accept a normal scan as the end of it if your symptoms persist. Normal imaging does not exclude the diagnosis¹.

Separate the three pain types before you assume the drug caused it. If lubricant helps a lot, you are probably in dryness territory. If it does nothing and the pain is deep, it was never a lubrication problem.

Raise the oral-hormone question if you are on tirzepatide and your endometriosis is managed with a daily pill.

Where this sits on the evidence scale

Painful sex is a core endometriosis symptom: strong. A 2025 JAMA review reports pelvic pain including dyspareunia in 90% of people with the condition.

Diagnosis is routinely delayed: strong. An average of 5 to 12 years, with most women consulting three or more clinicians.

Normal imaging rules it out: contradicted. The review states explicitly that normal examination and imaging do not exclude the diagnosis.

Lower BMI is associated with endometriosis: observational only. It is a listed risk factor, not a demonstrated cause, and it says nothing about the effect of losing weight.

GLP-1s cause, worsen or improve endometriosis: no evidence either way. Nothing has tested it.

Tirzepatide's four-week windows affect endometriosis symptom control: untested. The labels address contraceptive efficacy only. The mechanism makes the question reasonable; no study answers it.